Physician profile
Desiree Robison
NPI 1497162705
$2,453.75
in general payments reported to CMS, 2019-2025
28 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $195 · 2023: $1,009 · 2024: $925 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $349.51 | 2022-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $272.62 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $182.22 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $157.94 | 2022-2023 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $149.71 | 2022-2024 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $119.68 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $114.24 | 2023-2024 | Quviviq |
| Abbvie INC. | $106.29 | 2023-2025 | |
| Abbott Laboratories | $104.15 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.15 | 2022-2024 | Jardiance, Ofev |
| Phathom Pharmaceuticals, INC. | $87.81 | 2024 | Voquezna |
| Alkermes, INC. | $87.40 | 2025 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $80.45 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $76.94 | 2022-2023 | |
| Boston Scientific Corporation | $69.30 | 2023 | Resonate El Icd Vr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $64.31 | 2021-2023 | Trintellix |
| Aytu Biopharma, INC. | $56.58 | 2021 | |
| Sumitomo Pharma America, INC. | $53.02 | 2023-2024 | Gemtesa |
| Corium, LLC | $41.25 | 2022 | |
| Lundbeck LLC | $36.38 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.28 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $28.04 | 2025 | Invega Trinza, Invega Sustenna |
| Merck Sharp & Dohme LLC | $20.15 | 2024 | Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $17.49 | 2024 | |
| Dexcom, INC. | $17.31 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $13.05 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.88 | 2021 | |
| Adlon Therapeutics L.P. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.